Sentences with phrase «myxomatous mitral valve disease»

In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).

16 Tidholm A, Ljungvall I, Hoglund AB, Westling AB, Haggstrom J. Tissue Doppler and Strain Imaging in Dogs with Myxomatous Mitral Valve Disease in Different Stages of Congestive Heart Failure.

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.

The research provides a greater understanding of myxomatous mitral valve disease and heart failure in dogs

Parker, H. G. and Kilroy - Glynn, P. (1016), Myxomatous mitral valve disease in dogs: Does size matter?

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).

Results of prior studies have shown that the median time to onset of left ‑ sided CHF in dogs with stage B2 chronic myxomatous mitral valve disease (MMVD) is around 27 months.

The disease which causes the thickening and distortion of the mitral valve is known as myxomatous mitral valve disease and we will talk about this common condition some more in future articles.

Large and giant breeds of dog typically do not suffer from myxomatous mitral valve disease to the same extent as smaller dogs.

The licence for Vetmedin (Boehringer Ingelheim) has been extended to cover dogs with asymptomatic myxomatous mitral valve disease (MMVD).

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.

The EPIC Study was the largest clinical study ever to be conducted amongst dogs with myxomatous mitral valve disease (MMVD).

«Left Atrial Rupture Secondary to Myxomatous Mitral Valve Disease in 11 dogs.»

Pimobendan is recommended for the treatment of CHF in dogs caused by dilated cardiomyopathy (DCM) or myxomatous mitral valve disease (MMVD).4

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.

The following simple screening process has been developed to help you determine whether dogs suspected to have myxomatous mitral valve disease (MMVD) have evidence of disease progression.

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study — a randomized clinical trial.

Important biomarkers have been found in extracellular vesicles in dogs with myxomatous mitral valve disease (MMVD) and congestive heart failure, according to researchers at Cummings School of Veterinary Medicine at Tufts University in Grafton, Mass..

The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).

His research interests include interventional cardiology, diagnosis and treatment of myocarditis, myxomatous mitral valve disease and cardiac biomarkers.

This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy in treating dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).

AKC / CHF GRANT # 00908: Serotonin Type2A Receptor Antagonist Therapy for Preventing the Progression of Myxomatous Mitral Valve Disease.

Murmurs on the left side of the heart are most often caused by myxomatous mitral valve disease (MMVD), stenoses of aortic or pulmonary valves, or patent ductus arteriosus (PDA).

Heart Mitral Valve Disease (MVD), or more correctly, myxomatous mitral valve disease (MMVD) is the leading cause of death of Cavalier King Charles Spaniels throughout the world.

Currently, there are active research programs involving management of congestive heart failure, myxomatous mitral valve disease, feline cardiomyopathy, thrombosis and antithrombotic therapy, pacemaker therapy, and correction of congenital cardiac disease.

Myxomatous mitral valve disease (MMVD) is the single most common acquired heart disease of the dog, but is also of emerging importance in human medicine, with some features of the disease shared between both species.

Myxomatous mitral valve disease (MMVD) is the single most common acquired heart disease of the dog, but is

The trial, titled «Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.

Use of discriminant analysis based on echocardiography for classification of congestive heart failure in dogs with myxomatous mitral valve disease.

Mitral regurgitation (MR), secondary to myxomatous mitral valve disease (MMVD), is the most common cardiac disorder in dogs and is usually caused by progressive degeneration of the atrioventricular valves.

A breeding program with the aim of reducing the prevalence of mitral regurgitation (MR) caused by myxomatous mitral valve disease (MMVD) in Cavalier King Charles Spaniels (CKCS) is currently ongoing in Sweden.

Interventional Cardiology, Diagnosis and Treatment of Myocarditis, Myxomatous Mitral Valve Disease, and Cardiac Biomarkers